» Articles » PMID: 28916247

Comparison of Two Control Groups for Estimation of Oral Cholera Vaccine Effectiveness Using a Case-control Study Design

Overview
Journal Vaccine
Date 2017 Sep 17
PMID 28916247
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Case-control studies to quantify oral cholera vaccine effectiveness (VE) often rely on neighbors without diarrhea as community controls. Test-negative controls can be easily recruited and may minimize bias due to differential health-seeking behavior and recall. We compared VE estimates derived from community and test-negative controls and conducted bias-indicator analyses to assess potential bias with community controls.

Methods: From October 2012 through November 2016, patients with acute watery diarrhea were recruited from cholera treatment centers in rural Haiti. Cholera cases had a positive stool culture. Non-cholera diarrhea cases (test-negative controls and non-cholera diarrhea cases for bias-indicator analyses) had a negative culture and rapid test. Up to four community controls were matched to diarrhea cases by age group, time, and neighborhood.

Results: Primary analyses included 181 cholera cases, 157 non-cholera diarrhea cases, 716 VE community controls and 625 bias-indicator community controls. VE for self-reported vaccination with two doses was consistent across the two control groups, with statistically significant VE estimates ranging from 72 to 74%. Sensitivity analyses revealed similar, though somewhat attenuated estimates for self-reported two dose VE. Bias-indicator estimates were consistently less than one, with VE estimates ranging from 19 to 43%, some of which were statistically significant.

Conclusions: OCV estimates from case-control analyses using community and test-negative controls were similar. While bias-indicator analyses suggested possible over-estimation of VE estimates using community controls, test-negative analyses suggested this bias, if present, was minimal. Test-negative controls can be a valid low-cost and time-efficient alternative to community controls for OCV effectiveness estimation and may be especially relevant in emergency situations.

Citing Articles

Evaluation of pre-exposure vaccine effectiveness against mpox during the 2022-2023 mpox outbreak in the Madrid region (Spain): a test-negative design.

Barbas Del Buey J, Inigo Martinez J, Alonso Garcia M, Aragon Pena A, Montero Morales L, Arce Arnaez A BMJ Public Health. 2025; 2(1):e000620.

PMID: 40018242 PMC: 11812824. DOI: 10.1136/bmjph-2023-000620.


Euvichol-plus vaccine campaign coverage during the 2017/2018 cholera outbreak in Lusaka district, Zambia: a cross-sectional descriptive study.

Mukonka V, Sialubanje C, Matapo B, Chewe O, Ngomah A, Ngosa W BMJ Open. 2023; 13(10):e070796.

PMID: 37798024 PMC: 10565249. DOI: 10.1136/bmjopen-2022-070796.


Estimating the proportion of clinically suspected cholera cases that are true Vibrio cholerae infections: A systematic review and meta-analysis.

Wiens K, Xu H, Zou K, Mwaba J, Lessler J, Malembaka E PLoS Med. 2023; 20(9):e1004286.

PMID: 37708235 PMC: 10538743. DOI: 10.1371/journal.pmed.1004286.


Poor Sensitivity of Stool Culture Compared to Polymerase Chain Reaction in Surveillance for in Haiti, 2018-2019.

Guillaume Y, Debela M, Slater D, Vissieres K, Ternier R, Franke M Open Forum Infect Dis. 2023; 10(6):ofad301.

PMID: 37383250 PMC: 10296062. DOI: 10.1093/ofid/ofad301.


An Age-stratified, Randomized Immunogenicity Trial of Killed Oral Cholera Vaccine with Delayed Second Dose in Cameroon.

Ateudjieu J, Sack D, Nafack S, Xiao S, Tchio-Nighie K, Tchokomeni H Am J Trop Med Hyg. 2022; 107(5):974-983.

PMID: 36395746 PMC: 9709001. DOI: 10.4269/ajtmh.22-0462.


References
1.
Allan M, Grandesso F, Pierre R, Magloire R, Coldiron M, Martinez-Pino I . High-resolution spatial analysis of cholera patients reported in Artibonite department, Haiti in 2010-2011. Epidemics. 2016; 14:1-10. DOI: 10.1016/j.epidem.2015.08.001. View

2.
Azman A, Parker L, Rumunu J, Tadesse F, Grandesso F, L Deng L . Effectiveness of one dose of oral cholera vaccine in response to an outbreak: a case-cohort study. Lancet Glob Health. 2016; 4(11):e856-e863. DOI: 10.1016/S2214-109X(16)30211-X. View

3.
Page A, Ciglenecki I, Jasmin E, Desvignes L, Grandesso F, Polonsky J . Geographic distribution and mortality risk factors during the cholera outbreak in a rural region of Haiti, 2010-2011. PLoS Negl Trop Dis. 2015; 9(3):e0003605. PMC: 4374668. DOI: 10.1371/journal.pntd.0003605. View

4.
Belongia E, Simpson M, King J, Sundaram M, Kelley N, Osterholm M . Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016; 16(8):942-51. DOI: 10.1016/S1473-3099(16)00129-8. View

5.
Boncy J, Rossignol E, Dahourou G, Hast M, Buteau J, Stanislas M . Performance and utility of a rapid diagnostic test for cholera: notes from Haiti. Diagn Microbiol Infect Dis. 2013; 76(4):521-3. DOI: 10.1016/j.diagmicrobio.2013.03.010. View